<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Many substances have been shown to reduce brain damage in models of <z:hpo ids='HP_0001297'>stroke</z:hpo>, but mainly when given either before or shortly after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Delayed systemic administration of pituitary adenylate cyclase-activating <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (PACAP) has been shown to attenuate the neuronal damage in the hippocampus in a model of global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>The present study examined the neuroprotective action of delayed systemic administration of PACAP38 in a model of transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> produced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in rats </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We administered PACAP38 as an intravenous bolus (20 nmol/kg body wt) followed by an intravenous infusion for 48 hours using a micro-osmotic pump at a rate of 160 pmol/microL per hour, beginning 4, 8, or 12 hours after a 2-hour transient MCAO using a filament model </plain></SENT>
<SENT sid="4" pm="."><plain>The size of the <z:mpath ids='MPATH_124'>infarct</z:mpath> was determined by examining 2-mm-thick brain sections stained with triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi>, followed by image analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Control animals received intravenously 0.1% bovine serum albumin in 0.9% saline as a bolus and infusion at the same time intervals </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The administration of PACAP38 beginning 4 hours after MCAO significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> size by 50.88% </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with PACAP38 starting 8 or 12 hours after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> did not result in a significant reduction of the <z:mpath ids='MPATH_124'>infarct</z:mpath> size, although <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes tended to be smaller than in the control groups </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Systemic administration of PACAP38 should be clinically useful for reducing brain damage resulting from <z:hpo ids='HP_0001297'>stroke</z:hpo> even when administration is delayed for several hours </plain></SENT>
</text></document>